ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was down 13.9% on Monday . The stock traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.30 ($0.03). Approximately 622,206 shares were traded during trading, a decline of 94% from the average daily volume of 10,522,184 shares. The stock had previously closed at GBX 2.68 ($0.04).
ImmuPharma Stock Performance
The company has a 50-day moving average of GBX 3.39 and a 200-day moving average of GBX 2.53. The firm has a market capitalization of £10.20 million, a price-to-earnings ratio of -4.15 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- How to Buy Cheap Stocks Step by Step
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- P/E Ratio Calculation: How to Assess Stocks
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- What is the Nasdaq? Complete Overview with History
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
